Impacts of Cost-Effectiveness Assessments on Patient Access in PDAB States

Impacts of Cost-Effectiveness Assessments on Patient Access in PDAB States

Prescription Drug Affordability Boards (PDABs) are emerging as a tool for states to address rising drug costs; in some states, PDABs are authorized to create upper payment limits (UPLs) on medications deemed unaffordable. However, the potential for states to set UPLs using cost-effectiveness assessments, such as those from the Institute for Clinical and Economic Review…